Učitavanje...
Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
Little is known about sleep-based approaches to the treatment of nocturnal enuresis (NE). This report is the first to describe the successful use of suvorexant, an orexin receptor antagonist, in a 12-year-old boy with intractable NE. With suvorexant, the frequency of NE gradually decreased from 14 o...
Spremljeno u:
| Izdano u: | BMJ Case Rep |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Publishing Group
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970267/ https://ncbi.nlm.nih.gov/pubmed/33727289 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-239621 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|